Home > Healthcare & Medical Devices > Respiratory Disease Testing Market

Respiratory Disease Testing Market Size By Test Type (Mechanical Tests {Spirometry, Peak-flow Test, Pulmonary Function Test, Blood Gas Test), Imaging Tests {X-ray, CT-scan, Ultrasonography, MRI}, In-vitro Diagnostic Tests {Point-of-care Test, Molecular Diagnostic Test}), By Application (Chronic Obstructive Pulmonary Disease, Lung Cancer, Asthma, Tuberculosis) By End-use (Diagnostic Centers, Hospitals, Clinics), Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2020 – 2026

  • Report ID: GMI1871
  • Published Date: Apr 2020
  • Report Format: PDF

Industry Trends

Respiratory Disease Testing Market size was over USD 10 billion in 2019 and shall exhibit close to 8.5% CAGR throughout the forecast timespan. Respiratory disease testing is widely used to measure lung disorders by measuring the capacity to hold, move air and to absorb oxygen. The industry growth is attributed to the rise in respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, tuberculosis, and COVID-19 among others.

Get more details on this report - Request Free Sample PDF

Rise in incidence of COVID-19 has led to patient suffering from respiratory distress, thereby increasing the demand for respiratory disease testing. According to World Health Organisation (WHO), till 15th March 2020, approximately 3,204 deaths were registered in China due to COVID-19 outbreak. These cases were associated with severe acute respiratory syndrome (SARS) and thus resulted in increased respiratory disease testing across China. Also, the adoption of imaging technologies in developed as well as developing regions has increased in the past few years.

Recent surge in coronavirus cases globally together with the rise in geriatric population will boost the market growth

The growing coronavirus cases especially in the countries such as the U.S., Italy, Spain, South Korea, and Japan among others has resulted in the increased respiratory disease testing across various healthcare settings. For instance, as of March 17th, 2020, there were a total 2.1 million cases globally. Also, total deaths related to COVID 19 were around 144,221 and around 80% of the individuals were aged 60 and over. Geriatric population are more susceptible to various illnesses such as cardiovascular diseases, diabetes, and respiratory disorders. Thus, routine use of respiratory diagnostic devices among the geriatric population will drive the respiratory disease testing market growth.

Increasing adoption of pulmonary and spirometry test for efficient diagnosis

Get more details on this report - Request Free Sample PDF

Mechanical tests segment was valued around USD 3.2 billion in 2019 and is estimated to grow significantly during 2020 to 2026. The major factors boosting the market growth are increasing number of chronic and infectious disease coupled with rising rate of air pollutants and hazardous gases. For instance, as per the Asthma and Allergy Foundation of America (AAFA), approximately 25 million individuals suffer from asthma in the U.S. alone. Asthma is one of the most common diseases among children and affects 14% of children globally.

Spirometry test is considered to be of significant importance as it measures vital capacity as well as forced expiratory volume in less than one second. Thus, spirometry segment is expected to register a higher CAGR during the forecast period due to its efficacy and accuracy in diagnosis.

Increasing consumption of tobacco smoke and exposure to outdoor pollutants

Get more details on this report - Request Free Sample PDF


COPD segment held the largest revenue in 2019 and is projected to expand at 9.1% CAGR during 2020 to 2026 due to increasing prevalence of COPD cases globally. Increasing consumption of cigarettes by individuals will eventually lead to respiratory disorders, thereby creating the need for respiratory disease testing. Additionally, increasing R&D investment to develop the advanced treatment options for COPD will further offer various opportunities, thereby augmenting the respiratory disease testing market growth.

Availability of advanced imaging modalities in hospitals will boost the global market growth

Hospitals held a significant application share in 2019 and was valued at USD 3.7 billion. Hospitals are well equipped with advanced imaging modalities such as CT-scan, X-ray and MRI machines. Thus, increased adoption of imaging modalities for diagnostic purposes in hospitals will further drive the segmental growth.

Moreover, increasing number of COVID-19 cases will further boost the demand of respiratory disease testing in hospitals. For instance, as per the European society of anaesthesiology, by 20 March 2020, the rate of increase in number of patient suffering from COVID-19 were peaked at high level in Italy. Furthermore, these imaging devices have greater significance in outpatient and emergency departments as a preferred diagnostic tool for various types of diseases.

High prevalence of chronic and infectious diseases in North America

Prevalence of various chronic and infectious diseases in the North America region is one of the key factors responsible for regional growth. Increasing prevalence of COVID-19 infection will serve as major impact rendering factor for market growth. Till 17th April 2020, approximately 6.7 million cases of COVID-19 were registered in U.S. Majority of active cases are been diagnosed with respiratory illness such as coughing and sneezing. Furthermore, well developed healthcare infrastructure, robust distribution channel for diagnostic devices and increased awareness levels will drive the respiratory disease testing industry growth in the region.

Implementation of various strategies such as new product launch and collaborations is expected to create profitable opportunities

Some of the prominent players operating in the respiratory disease testing market include Becton Dickinson & Company, Koninklijke Philips N.V., ResMed and Fischer & Paykel, among others. These major industry players are focusing on various inorganic and organic strategies to launch new devices and mergers & acquisitions to sustain market growth and competition.

Recent industry developments:

  • In March 2020, Abbot received Emergency Use Authorization (EUA) from U.S. FDA for ID NOW platform. The device is used as molecular point-of-care test to detect novel coronavirus symptoms such as influenza, respiratory syncytial and strep throat. Thus, introduction of novel products will result in the increased sales revenue for the company.
  • In March 2020, Medtronic launched two solutions designed to monitor the patients suffering from COVID-19 and their respiratory symptoms. The virtual care evaluation and monitoring solutions are also made available to the health plans, employers, and U.S. health systems. Thus, the company would benefit from aforementioned solution’s sales.

The respiratory disease testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2015 to 2026, for the following segments:

By Test type

  • Mechanical Tests
    • Spirometry
    • Peak-flow Test
    • Pulmonary Function Test
    • Blood Gas Test
    • Others
  • Imaging Tests
    • X-ray
    • CT-scan
    • Ultrasonography
    • MRI
  • In-vitro Diagnostics Tests
    • Point-of-care Test
    • Molecular Diagnostic Test
    • Others

By Application

  • Chronic Obstructive Pulmonary Disease
  • Lung Cancer
  • Asthma
  • Tuberculosis
  • Others

By End-use

  • Diagnostic Centres
  • Hospitals
  • Clinics
  • Others

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • Italy
    • Spain
    • France
    • Netherlands
    • Switzerland
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia
    • South Korea
    • Malaysia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Chile
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Turkey
    • Egypt


Authors: Rupali Swain, Subodh Kharad

Frequently Asked Questions (FAQ) :

The market size of respiratory disease testing exceeded USD 10 billion in 2019.
The industry share of respiratory disease testing is projected to grow at 8.5% CAGR during 0020 to 2026.
COPD application held the largest revenue in 2019 and is projected to expand at 9.1% CAGR during 2020 to 2026 due to increasing prevalence of COPD cases globally.
Mechanical tests segment was valued around USD 3.2 billion in 2019.
Prevalence of various chronic and infectious diseases in the North America along with increasing prevalence of COVID-19 infection is one of the key factors responsible for regional growth.

Buy Now

Premium Report Details

  • Base Year: 2019
  • Companies covered: 12
  • Tables & Figures: 432
  • Countries covered: 23
  • Pages: 200
  • Upcoming Report: Details can be customized to meet your information and data needs. Feel free to share your detailed research requirements via this form.

Get a report that explains COVID-19 impact on this market

 Request Free Sample

Budget constraints? Get in touch with us for special pricing

Request Discount